Hutchin Hill Capital’s Charles River Laboratories CRL Stock Holding History

Hutchin Hill Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-7,500	Closed	-$810K	–	456
2017 Q3	$810K	Buy	+7,500	New	+$771K	0.03%	387
2017 Q2	–	Sell	-4,500	Closed	-$405K	–	864
2017 Q1	$405K	Buy	+4,500	New	+$382K	0.01%	740
2016 Q3	–	Sell	-16,500	Closed	-$1.36M	–	618
2016 Q2	$1.36M	Buy	+16,500	New	+$1.36M	0.05%	232
2015 Q4	–	Sell	-93,100	Closed	-$5.91M	–	647
2015 Q3	$5.91M	Buy	93,100 +65,400	+236%	+$4.7M	0.23%	125
2015 Q2	$1.95M	Buy	+27,700	New	+$2.05M	0.05%	325
2015 Q1	–	Sell	-48,000	Closed	-$3.06M	–	682
2014 Q4	$3.06M	Buy	48,000 +20,900	+77%	+$1.31M	0.11%	160
2014 Q3	$1.62M	Sell	27,100 -60,300	-69%	-$3.45M	0.06%	281
2014 Q2	$4.68M	Buy	+87,400	New	+$4.8M	0.21%	80
2013 Q4	–	Sell	-18,400	Closed	-$851K	–	536
2013 Q3	$851K	Buy	+18,400	New	+$844K	0.08%	192

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hutchin Hill Capital's CRL Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 7,500 shares — an estimated $810K sold.

Hutchin Hill Capital first reported a position in CRL in Q3 2013 and held it in 9 quarters. The position peaked at $5.91M in Q3 2015. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

Hutchin Hill Capital reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 7,500 Charles River Laboratories shares in Q4 2017, an estimated $810K.
Hutchin Hill Capital first reported a position in Charles River Laboratories in Q3 2013 and held it in 9 quarters.
Hutchin Hill Capital's Charles River Laboratories position peaked at $5.91M in Q3 2015.
339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.